2. Anticorps inhibiteurs
  3. Biosimilar Antibodies
  4. Monoclonal Antibodies
  5. Romosozumab

Romosozumab  (Synonyms: AMG-785; CDP-7851)

Cat. No.: HY-P9982 Pureté: 99.11%
COA
SDS
Technical Support

Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No. : 909395-70-6

Size Prix Stock Quantité
Échantillon gratuit (100 μg)   Appliquer maintenant  
1 mg En stock
5 mg En stock
10 mg En stock
25 mg En stock
50 mg En stock
100 mg En stock
200 mg   Obtenir un devis  
500 mg   Obtenir un devis  

* Veuillez sélectionner la quantité avant d'ajouter des articles.

This product is a controlled substance and not for sale in your territory.

Romosozumab Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Romosozumab

  • Activité biologique

  • Pureté et documentation

  • Références

  • Avis client

Description

Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis[1][2].

Isotype

Human IgG2 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

SOST/Sclerostin
In Vivo

Romosozumab (30 mg/kg; s.c. twice a week for 10 weeks) converts trabecular rods into trabecular plates in cynomolgus monkeys[1].
Romosozumab (3 and 30 mg/kg; s.c. once a week for 6 or 12 months) improves bone mass, architecture, and bone strength, and maintains bone quality at the same time in mature cynomolgus monkeys with 4 months post-ovariectomy[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male cynomolgus monkeys[1]
Dosage: 30 mg/kg
Administration: Subcutaneous injection; 30 mg/kg twice a week for 10 weeks
Result: Increased bone formation and plate-like trabecular morphology, and improved mechanical performance.
Essai clinique
Gene ID

50964  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Masse moléculaire

146.32 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Romosozumab]
Livraison

Shipping with dry ice.
Formulation

Please refer to the lot-specific COA for specific buffer information.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG2 kappa
Biological Activity
  • Immobilized SOST Protein, Human can bind Romosozumab. The EC50 for this effect is 12.46 ng/mL.
Pureté et documentation

Purity: 99.11%

SDS (251 KB)

COA (232 KB) SDS-PAGE (105 KB) SEC-HPLC (68 KB)

Inhibitory Antibodies User Guide (603 KB)
Références
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Romosozumab Related Classifications

  • Calculateur de molarité

  • Calculateur de dilution

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Romosozumab909395-70-6AMG-785 CDP-7851AMG785AMG 785CDP7851CDP 7851CDP-7851Othersmonoclonalbone formationbone resorptionsclerostinosteoporosisInhibitorinhibitorinhibit

Vos produits récemment consultés:

Demande en ligne

Your information is safe with us. * Required Fields.

Nom du produit

  

Requested Quantity *

Nom du demandeur *

 

Civilité

Adresse e-mail *

 

Numéro de téléphone *

Department

 

Nom de l'organisation *

City

État

Country or Region *

      

Remarques

Bulk Inquiry

Inquiry Information

Nom du produit:
Romosozumab
Cat. No.:
HY-P9982
Quantité:
MCE Japan Authorized Agent:

Avis client

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Nom du produit

  

Lot #

Nom du demandeur *

 

Adresse e-mail *

Numéro de téléphone

 

Department *

Nom de l'organisation *

 

Country or Region *

Remarques

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Korean - KR (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.